AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05114109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isatuximab Injection
Description: Isatuximab will be given intravenously at 10mg/kg at day 0, week (W)1, W2, W3, and W4 then every 2 weeks for a total of 12 infusions.
Study NCT04820101 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: administrating dexmedetomidine in order to evaluate the efficacy in achieving sedation for LISA procedure
Study NCT05333887 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PFC+
Description: Therapists instruct parents in ways to coach their children to display better friendship behaviours using skill teaching and home practice. The program includes 2 intake sessions, a group workshop where all strategies are reviewed, and 3 consultation sessions to work on implementing strategies with therapist support. Emphasis throughout the program is placed on parents' connection and engagement with the material and therapist.
Study NCT05771090 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sokru device
Description: Different induced glycaemic states in people living with diabetes (PwD).
Study NCT04993963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycle Ergometery Training (Prehabilitation)
Description: Interval training on cycle ergometer: between 40% and 60% Vo2max, perceived exertion \<13 on Borg scale 20-30 min/session/day (intermittent of exercise 2-3 mint, followed by 1-2 min of active recovery) Cool down (5 minutes) AROM +Body stretch
Study NCT04993963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Standard Group
Description: Breathing exercise 15 Reps and Walk (10-15 minutes)
Study NCT06453902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TGRX-678
Description: All patients will be given TGRX-678 240 mg once daily. TGRX-678 is to be taken orally
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adaptive Activity Goals (Weekly)
Description: Physical activity goals that adapt once each week using the participants' data derived from activity tracker.
Study NCT06204796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic prednisone
Description: All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case. In addition, a vitamin D supplement was given as 60,000 IU weekly in conjunction with systemic steroids.
Study NCT06204796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Systemic prednisone
Description: All participants received 40-60 mg of systemic prednisone as a single morning dose according to the severity of the condition until a 50% reduction in lesion size was achieved then the dose was tapered by 10mg each week and finally to 5 mg/day for the last week. Patients were followed up weekly for up to 60 days. The length and dose of treatment were adjusted according to clinical needs in each case.
Study NCT06234865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients in the control group will receive standard education plus a brochure education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The brochure education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
Study NCT06234865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Video Education Group
Description: Patients in the experimental group will receive standard education plus a video education. Standard education includes education provided by the doctor, nurse and/or physiotherapist before and after surgery. The video education includes information about constipation and interventions that can be used to prevent constipation such as nutrition, fluid intake, physical activity, leg exercises, abdominal massage, and toilet habits.
Study NCT05819190 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Healsea Rescue*
Description: Subjects will be administered with Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
Study NCT05819190 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be administered with isotonic saline nasal spray indistinguishable from the Healsea Rescue\* by spraying 2 puffs in each nostril 2 times per day during 7 days.
Study NCT05302791 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Muscle Cooling
Description: Cooling wrap will be set to 10°C
Study NCT05302791 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Exercise
Description: Resistance Machines (Leg Press and Knee extension). 12 rep Max
Study NCT05302791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Resistance Machines (Leg Press and Knee extension). 12 rep Max
Study NCT04495634 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stationary Head CT (s-HCT)
Description: The system consists of a total of three x-ray sources and nine x-ray detectors with an estimation of approximately 150 projection angles per slice, with less than a minute per slice reconstruction. Radiation dose will be configured as to not exceed that of a conventional head CT, or 2 mSv. The subjects will be positioned on a medical procedure table that will move the subject through the scanning system at the rate of roughly 1 cm per second, during which the necessary x-ray projections will be acquired. The head will be positioned in a carbon fiber head holder from a clinical CT scanner that is secured to the table.
Study NCT04853576 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EDIT-301
Description: Administered by IV infusion after myeloablative conditioning with busulfan.
Study NCT04518930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peanuts or plain Greek yogurt
Description: Two different types of dietary snacks
Study NCT05133362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gait training with EksoNR
Description: Participants will receive forward gait training with EksoNR
Study NCT05133362 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait training with EksoNR
Description: Participants will receive forward gait training with EksoNR
Study NCT05133362 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Backward gait training with EksoNR
Description: Participants will receive backward gait training with EksoNR
Study NCT05457361 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VEN combined with azacitidine plus homoharringtonine
Description: VEN begins at 100 mg on day 1 and increases stepwise over 3 days to reach the target dose of 400 mg (100 mg, 200 mg, 400 mg); dosing is continued at 400 mg per day from day 4 through day 14; azacitidine (75 mg/m²) is administered subcutaneously on days 1-7, and HHT (1 mg/m²) on days 1-7.
Study NCT05457361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VEN combined with azacitidine
Description: The use of VEN is just the same as it dose in VAH regimen except lasting for 28 days. The use of azacitidine is exactly the same as VAH group does.
Study NCT06123117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single transversus abdominis laparoscopy-guided plane block
Description: please see arm/group descriptions
Study NCT06123117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local trocar site ropivacaine infiltration
Description: please see arm/group descriptions
Study NCT06123117 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local trocar site ropivacaine infiltration
Description: please see arm/group descriptions
Study NCT06550115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating
Description: Night shift workers will participate in 4 weeks of fasting during the biological nighttime while remaining awake during overnight work shifts.
Study NCT06550115 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control eating
Description: Night shift workers will participate in 4 weeks of Control eating across the daytime and nighttime hours while remaining awake during overnight work shifts.
Study NCT04895566 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (Mab) sB24M
Description: 200 mg monoclonal antibody (Mab) sB24 by injection into the affected areas.
Study NCT05119660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intermittent Theta Burst Stimulation
Description: iTBS
Study NCT06217354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin 100 Microgram/mL Solution for Injection
Description: All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
Study NCT06217354 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carbetocin 100 Microgram/mL Solution for Injection
Description: All patients will receive a bolus of carbetocin 100mcg IV over one minute after cord clamping. \[PabalVR, Ferring AG, Baar, Switzerland\]).then assess uterine contractility and postpartum bleeding measuring
Study NCT05707052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neck-Trunk Stabilization Exercises and conventional physical therapy
Description: Neck-Trunk Stabilization Exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
Study NCT05707052 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bobath Therapy and conventional physical therapy
Description: Bobath based exercises along with conventional physical therapy in which stretching, strengthening, ROMs positioning and electrical stimulation are included.
Study NCT05649098 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
Study NCT05689216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Awake timed prone and repositioning
Description: Patients were instructed to adopt a timed prone and repositioning strategy with 4 sessions for four consecutive days.~Session 1, lying on the belly; Session 2, lying on the right side; Session 3, sitting up; Session 4, lying on the left side; then back to session 1 (30 minutes to two hours for each session). The daily duration of timed prone and repositioning is strongly recommended for 8-10 hours.
Study NCT04467515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAM-H2
Description: All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
Study NCT04887688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: exciflex
Description: untethered electronic bandage with all the components of a surface stimulation system mounted on a flexible substrate.
Study NCT06253130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMP1734
Description: PARP1 selective inhibitor
Study NCT06306365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modern board game-based learning
Description: Modern board game-based learning involves using contemporary board games as educational tools. It emphasizes active participation, critical thinking, and social interaction among participants. By integrating strategic thinking and problem-solving within a game context, this approach aims to enhance learning experiences in an engaging and enjoyable manner. In this study, board games have been selected to target and engage executive functions.
Study NCT04732039 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measurement of peak oxygen uptake
Description: Oxygen uptake measured on bike (pVO2) and during the conduction of specific daily life activities (ADL-VO2).
Study NCT04888585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-154
Description: Subcutaneous Injection
Study NCT04888585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection
Study NCT04927975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablets
Study NCT04927975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Points (Fixed)
Description: Message timing is fixed and evaluated at specific times each day to determine message eligibility.
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Points (Adaptive)
Description: Message timing is adaptive and derived from individual user data to determine message eligibility.
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Standard)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors.
Study NCT05123638 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual reality cycling exercise
Description: Daily voluntary cycling for up to 30 minutes with the virtual reality technology
Study NCT06357858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INQOVI (decitabine and cedazuridine)
Description: Oral decitabine (ASTX727) will be administered during D1-5 (DL1) or D1-4 (DL1-1).
Study NCT06357858 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be administered on D8 with every 4 week cycle.
Study NCT06441669 — intervention group
Intervention type: DRUG
Intervention: Letermovir
Description: Patients will be given Letermovir with a recommended dose from +1 day to +100 days after UCBT.
Study NCT05123638 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unsupervised stationary cycling exercise
Description: Daily voluntary cycling for up to 30 minutes (WITHOUT the virtual reality technology)
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Decision Rules (Adaptive)
Description: Decision rules to determine eligibility to receive just-in-time messages consider participant's recent behaviors and overall progress.
Study NCT05251285 — intervention group
Intervention type: PROCEDURE
Intervention: Nipple-Sparing Mastectomy
Description: Nipple-Sparing Mastectomy using da Vinci X/Xi Surgical System
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (No)
Description: Participant choice does not drive adaptation of 1) message type delivered or 2) lapse support provision
Study NCT06533917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Main Group
Description: Thoracolumbar spine AP, Thoracolumbar spine LAT
Study NCT05247593 — intervention group
Intervention type: DRUG
Intervention: Dayingpian
Description: The actual dosage of Dayingpian is adjusted according to the patient's condition. The recommended dosage of Dayingpian is 5-10 tablets each time, 2-3 times a day.
Study NCT05247593 — intervention group
Intervention type: DRUG
Intervention: conventional mood stabilizers
Description: Patients in the group are treated with the standard level of conventional mood stabilizers provided by psychiatrists according to treatment guidelines for bipolar disorder.
Study NCT04922216 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Message Choice (Yes)
Description: Participant choice drives adaptation of 1) message type delivered and 2) lapse support provision.
Study NCT06167564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Routine allergy tests
Description: Prick test, specific IgE detection
Study NCT06167564 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Newly developed microarray-based diagnostic test system
Description: Newly developed microarray-based diagnostic test system for the detection of the specific IgE
Study NCT05650866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activation of pro-erectile nerves within the pelvic plexus
Description: The study device is an active implantable device. The device activates the cavernous nerves by delivering electrical pulses, to trigger an on-demand erection. The daily delivery of electrical pulses to the cavernous nerves will also allow participants to recover natural erectile function.
Study NCT06221449 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Positive end expiratory pressure
Description: The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O.
Study NCT06221449 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positive end expiratory pressure
Description: The patients will be divided into three groups:~Control group:(31 patients); Patients will have controlled mechanical ventilation with these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate10-14 RR/min) II) Group (II) Sustained inflation group (SI): (31 patients); Patients will have controlled mechanical ventilation then after abdominal deflation, sustained inflation for 30 second by applying pressure 40 cmH2O, with 5 these parameters (fixed Tidal Volume 6-8ml/Kg IBW - fixed fio2 0.5% - fixed PEEP 6 cmH2O - fixed respiratory rate 10-14 RR/min) III) Group (III) Stepwise PEEP increasing: (31 patients); Patients will have controlled mechanical ventilation, then after abdominal deflation gradual increasing in PEEP 2 cmH2O every 5 respiratory cycle with maximum 10-12 cmH2O guided by hemodynamics \& airway pressure not exceeding 40 cmH2O.
Study NCT05712395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
Study NCT05712395 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Non-Ischemic Exercise (NICE), pain-free exercise program will be compared to the Standard painful exercise program.
Study NCT06545617 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BAT8006 for Injection
Description: Intravenous infusion: once every three weeks.The infusion time in the first cycle is recommended to be ≥ 90 minutes. If no infusion reaction occurs, the subsequent cycle can be completed within 30\~60 minutes.
Study NCT06681766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nomlabofusp
Description: Nomlabofusp is a recombinant fusion protein provided in a sterile, preservative-free buffered solution for subcutaneous injection intended to deliver human frataxin, the protein deficient in Friedreich's ataxia.
Study NCT06681766 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo is a sterile, preservative-free, clear liquid for subcutaneous injection.
Study NCT06132789 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried
Description: This vaccine（1.0ml） is produced by Ab\&b Biotechnology Co., Ltd.JS. Subjects will receive the Rabies Vaccine（Human Diploid Cell）for Human Use,Freeze-dried vaccinated by intramuscular injection.
Study NCT05381844 — intervention group
Intervention type: OTHER
Intervention: Blood sampling
Description: 30 ml blood sampling for virological research
Study NCT05039307 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and motivational strategy
Description: The intervention will focus on the following topics A) Healthy diet: food pyramid, a healthy plate distribution, type of carbohydrates and fats, healthy cooking techniques and healthy oils. B) Physical activity: definition, types of physical activity, advantages and benefits, examples, active physical activity sessions. C) Weight control: strategies, benefits and healthy weight gain during pregnancy. D) Knowledge and awareness of T2DM and GDM: definition, prevention, management and complications. These topics will be delivered through individualized education, group sessions and focus groups. Participants will be provided with printed material at baseline and also during the individual education sessions at the household containing a brief summary of the topics covered. The motivational components of goal setting and the use of a pedometer will be incorporated explained during the individual education sessions. The intervention will be primarily delivered by trained peer educators.